Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Socie...(listed under Risk Factors and Caution...)

Date:11/2/2009

listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    Contact:
      Susan Watkins
      T. +1-570-957-2563
      susan.watkins@sanofipasteur.com
      www.sanofipasteur.us

SOURCE Sanofi Pasteur

'/>"/>

SOURCE Sanofi Pasteur Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
2. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
3. Sanofi-aventis Announces Second Quarter 2009 Results
4. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
5. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
6. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
7. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
8. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
11. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster